Laureate Pharma has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, a biotechnology company that develops targeted therapies and safer solutions for immune modulation and related medical needs. Under the agreement, Laureate will produce Tolera’s TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Terms of the agreement were not disclosed.     “We are pleased to work closely with Tolera to accelerate their antibody therapeu...